Home » Newsletters » BioWorld Science

BioWorld Science

April 15, 1999

View Archived Issues

DiagnoCure develops diagnostic for metastatic prostate cancer cells

SBIR grant to Genetronics for gene therapy delivery research

Steroidogenesis inhibitor tested in mouse model of hereditary blindness

FDA requires further info about Hepagene vaccine

AIDSVAX enters clinical trials at U. of Pittsburgh

Merger plans for Synthelabo and Sanofi

Potent and specific FTase inhibitor presented by Biomeasure

Merck presents protein farnesyltransferase inhibitor in phase I testing

U.S. is country of first launch for single-isomer bronchodilator

PEG-rMETase, a promising new approach to cancer therapy

Preparation, compositions and administration of new carrier compounds reported by Emisphere

Fujirebio presents pyrimidine-based compounds useful for hypoxemia

Neurokinin antagonists for IBS synthesized and evaluated at Solvay

Schering-Plough investigators discover water-soluble salt of antifungal azole

Novel water-soluble camptothecin analogue suitable for formulation in liposomes

Sugen presents preclinical data for SU-6668 at AACR meeting

In vitro and in vivo antitumor effects of noscapine discussed at AACR meeting

Profile of ZD-4190, a potent VEGF receptor tyrosine kinase inhibitor and antiangiogenic agent

News from AACR: Abbott researchers report findings on farnesyltransferase inhibitors

TAS-106, a promising antitumor nucleoside profiled at AACR meeting

Ebastine is not approvable, FDA tells RPR

Ontogen's OC144-093 reported at AACR meeting to merit further clinical testing

Higher dose of Rebif approved in E.U. for multiple sclerosis

Antisense oligonucleotides targeting Bcl-x developed and evaluated at Isis

Elan holds pre-NDA meeting concerning ziconotide

NovoSeven reaches the U.S. hemophilia market

New distamycin derivative PNU-166196 exerts both antiproliferative and apoptotic effects

Celtrix and Elan form joint venture for osteoporosis therapy